Second-trimester double or triple screening for Down syndrome: A comparison of Chinese and Caucasian populations

被引:29
|
作者
Wang, Yuan-Yuan
Luo, Jun
Zhu, Ming-Wei
Liu, Lan-Nv
Ma, Xu
机构
[1] Natl Res Inst Family Planning, WHO Collaborating Ctr Res Human Reprod, Beijing 100081, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll, Beijing 100037, Peoples R China
[3] Int Peace Hosp Protect Mother & Childs Hlth, China Welf Inst, Shanghai, Peoples R China
[4] Fudan Univ, Obstet & Gynecol Hosp, Med Ctr, Shanghai 200433, Peoples R China
[5] Maternal & Fetal Hlth Hosp, Shanghai, Peoples R China
关键词
Down syndrome; prenatal screening; alpha fetoprotein; human chorionic gonadotrophin; unconjugated estriol;
D O I
10.1016/j.ijgo.2006.04.030
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: To compare the performance of double screening (measuring maternal serum levels of a-fetoprotein [AFP] and total beta-human chorionic gonadotrophin [hCG] as markers for Down syndrome) with that of triple screening (also measuring levels of unconjugated estriol [uE3]) in the second trimester of pregnancy, and to compare ethnic variance between Chinese and Caucasian populations. Methods: The study investigated 15096 normal singleton pregnancies and 24 pregnancies affected with Down syndrome. Frequency distributions of AFP, hCG, and uE3 levels were analyzed. Likelihood ratios (LRs) were calculated using the multiple of median value (MoM) of AFP, hCG, and uE3 as variables. After multiplying maternal age risk by the LR values for the markers used in double and triple screening, the specific risks obtained with double and triple screening were estimated. The detection rate (DR) and false-positive rate (FPR) were calculated at different cut-off points. The serum markers' levels were also compared with those of Caucasian women. Results: The median MoM value of hCG was higher in women with affected pregnancies (1.40) than those with unaffected pregnancies (1.00). However, the median MoMs of AFP and uE3 (0.79 and 0.68) were lower in affected than in unaffected pregnancies. At a FPR of 5%, the detection rates reached with double and triple screening were 50% and 66.7%, respectively. Ratios of the 3 serum markers' medians to those in a study with Caucasian women were 1.06 (range = 1.04-1.09) for AFP, 1.14 (range = 1.10-1.17) for hCG, and 1.28 (range = 1.23-1.41) for uE3 for the relevant gestational weeks. Conclusion: Triple screening performed better than double screening in the second trimester. Ethnic variance should be taken into account in Down syndrome screening. (c) 2006 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 50 条
  • [21] Combined first-trimester versus second-trimester serum screening for Down syndrome: A cost analysis
    Cusick, W
    Buchanan, P
    Hallahan, TW
    Krantz, DA
    Larsen, JW
    Macri, JN
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 188 (03) : 745 - 751
  • [22] Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome
    Muller, F
    Dreux, S
    Lemeur, A
    Sault, C
    Desgrès, J
    Bernard, MA
    Giorgetti, C
    Lemay, C
    Mirallié, S
    Beauchet, A
    PRENATAL DIAGNOSIS, 2003, 23 (13) : 1073 - 1076
  • [23] Second-trimester maternal serum invasive trophoblast antigen: A marker for down syndrome screening
    Pandian, R
    Cole, LA
    Palomaki, GE
    CLINICAL CHEMISTRY, 2004, 50 (08) : 1433 - 1435
  • [24] Interference in the autoDELFIA® hAFP immunoassay and effect on second-trimester Down's syndrome screening
    Taylor, Kevin P.
    Goodburn, Sandy
    Halsall, David J.
    ANNALS OF CLINICAL BIOCHEMISTRY, 2012, 49 : 412 - 413
  • [25] Combined first- and second-trimester screening for Down syndrome: an evaluation of proMBP as a marker
    Rode, L
    Wojdemann, KR
    Shalmi, AC
    Larsen, SO
    Sundberg, K
    Norgaard-Pedersen, B
    Christiansen, M
    Tabor, A
    PRENATAL DIAGNOSIS, 2003, 23 (07) : 593 - 598
  • [26] First- and second-trimester screening - Detection of aneuploidies other than down syndrome
    Breathnach, Fionnuala M.
    Malone, Fergal D.
    Lambert-Messerlian, Geralyn
    Cuckle, Howard S.
    Porter, T. Flint
    Nyberg, David A.
    Comstock, Christine H.
    Saade, George R.
    Berkowitz, Richard L.
    Klugman, Susan
    Dugoff, Lorraine
    Craigo, Sabrina D.
    Timor-Tritsch, Ilan E.
    Carr, Stephen R.
    Wolfe, Honor M.
    Tripp, Tara
    Bianchi, Diana W.
    D'Alton, Mary E.
    OBSTETRICS AND GYNECOLOGY, 2007, 110 (03): : 651 - 657
  • [27] Strict glycemic control in diabetic pregnancy - implications for second-trimester screening for Down syndrome
    Peled, Y
    Gilboa, Y
    Perri, T
    Shohat, M
    Chen, R
    Bar, J
    Hod, M
    Pardo, J
    PRENATAL DIAGNOSIS, 2003, 23 (11) : 888 - 890
  • [28] The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome
    Kadir, RA
    Economides, DL
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 1997, 9 (04) : 244 - 247
  • [29] Comparing three screening strategies for combining firstand second-trimester Down syndrome markers
    Skotko, Brian
    OBSTETRICS AND GYNECOLOGY, 2006, 107 (05): : 1170 - 1170